Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment

NCT02412787 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT02412787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02412787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment
Lead sponsor
Shire
Phase
Phase 2/3
Overall status
Completed
Start date
April 14, 2015
Completion date
April 18, 2024
Enrollment
56 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hunter syndrome